29 Engineering CD16-Enhanced Stem Cell–Derived Universal NKT Cells to Potentiate Anti-CD70 Therapy in Renal Cell Carcinoma
Yan-Ruide Li, Yichen Zhu, Yuning Chen, Thomas Yuen, Shelby Yeh · 2026
Read 29 Engineering CD16-Enhanced Stem Cell–Derived Universal NKT Cells to Potentiate Anti-CD70 Therapy in Renal Cell Carcinoma by Yan-Ruide Li, Yichen Zhu, Yuning Chen, Thomas Yuen, Shelby Yeh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13535433.txt.
Description
Kidney cancer often waves a flag called CD70, and an antibody drug that homes to it can summon killer cells — but weakly. Yan-Ruide Li and co-authors engineer a stronger partner: natural killer T cells grown from stem cells, fitted with a fixed receptor and a souped-up CD16 docking port, made as an off-the-shelf product. The cells are produced without feeder cells, at high purity, keeping their natural killing skills.
Paired with the antibody, the engineered cells destroyed CD70-positive kidney cancer cells in dishes and in animals far better than the antibody alone. They also lasted longer, stayed stable, and thinned out the tumour's suppressive neighbours, including certain macrophages and suppressor cells. Safety checks showed no runaway activation or off-target harm. The authors propose the combination as a template for next-generation cell-plus-antibody therapy of solid tumours.
Catalog record
| CREATOR | Yan-Ruide Li, Yichen Zhu, Yuning Chen, Thomas Yuen, Shelby Yeh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |